Kwality Pharmaceuticals : Q4 2024 Financial Quarterly Report : YoY Sales Up 33.68 %, QoQ Up 17.78 %

The comprehensive analytics outlining the performance and outlook of Kwality Pharmaceuticals Limited”s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Today, we’re looking at Kwality Pharmaceuticals Limited’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 33.68 %. However, it did see a marginal increase of 17.78 % from the previous quarter. Expenses ticked up slightly by 16.19 % quarter-on-quarter, aligning with the annual rise of 24.48 %. Operating profit, while up 79.7 % compared to last year, faced a quarter-on-quarter increase of 23.61 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 5.74 %, but an expansion of 1.06 % sequentially. Other income fell by -4.84 % compared to the last quarter, despite an annual decline of -59.59 %. Interest expenses surged remarkably by 12.09 % from the previous quarter, yet the year-over-year increase remains at a moderate 83.23 %. Depreciation costs climbed by 5.19 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 14.45 %. Profit before tax grew annually by 91.37 % but saw an increase from the preceding quarter by 34.12 %.
Tax expenses as a percentage of profits increased slightly by 52.73 % compared to last year, with a more notable quarter-on-quarter increase of 7.93 %. Net profit rose by 157.3 % year-on-year but witnessed a -44.79 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 156.43 % but a quarterly fall of -44.79 %. In summary, Kwality Pharmaceuticals Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

In reviewing Kwality Pharmaceuticals Limited’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 33.68 % year-on-year growth, however, there was a minor increase of 17.78 % from the previous quarter. Expenses rose by 24.48 % compared to the previous year, with a 16.19 % increase quarter-on-quarter. Operating Profit surged by 79.7 % annually, and saw a 23.61 % increase from the last quarter.
Net Profit showed yearly increase of 157.3 %, and experienced a -44.79 % decrease from the previous quarter. Earnings Per Share (EPS) rose by 156.43 % annually, however dipped by -44.79 % compared to the last quarter. In essence, while Kwality Pharmaceuticals Limited exhibits strong annual growth indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.